论文部分内容阅读
顿灵,国家一类新药,通用名盐酸吡格列酮胶囊,是新一代胰岛素增敏剂。于1 999年通过FDA认证。该药在美国上市前两个月,销售额即达4 80 0万美元,到2 0 0 1年年底,美国已有超过1 4 0万人服用该药。顿灵打破了传统降糖药物单一降糖的不足,集降糖调脂于一身,有效改善并发症,延缓糖尿病进程。他是通过增强机体对胰岛素的敏感性控制血糖,保护胰岛,并可以减少或改善糖尿病并发症,是唯一被批准与胰岛素合用的噻唑烷二酮类抗糖尿病药物。肾功能不全患者和老年患者不需调整剂量,每天一次,服药依从性好。顿灵是有效治疗2型糖尿病的一线用药。
Dayton, a class of new drugs, common name pioglitazone capsules, is a new generation of insulin sensitizers. In 1999 through the FDA certification. In the first two months of its marketing in the United States, the drug generated sales of 48 million U.S. dollars. By the end of 2001, more than 14 million people had taken the medicine in the United States. Dayton break the traditional hypoglycemic drugs a single hypoglycemic deficiencies, set hypoglycemic regulation in one, effectively improve the complications and delay the process of diabetes. He is the only thiazolidinedione antidiabetic drug approved for insulin administration by controlling the body’s insulin sensitivity to control blood sugar, protect the islets and reduce or improve diabetic complications. Patients with renal insufficiency and elderly patients do not need to adjust the dose, once a day, medication compliance. Dayton is effective first-line treatment of type 2 diabetes.